Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 9 to \< 48 months~2. IDA documented by hematologic indices (hemoglobin, MCV, RDW, reticulocyte count, reticulocyte hemoglobin content), serum ferritin, serum iron and total iron binding capacity~Exclusion Criteria:~1. Iron deficiency likely or definitely due to blood loss from the intestine or other sites.~2. Evidence of response to recent/current oral iron therapy, as determined by increase in hemoglobin by \> 1.0 gm/dL and MCV by 5 fL above measurements prior to iron therapy~3. History or evidence of intestinal malabsorption~4. History of prior intravenous iron therapy~5. Major co-morbidity such as a serious chronic medical condition unrelated to iron deficiency apparent on history, physical examination, or laboratory tests~6. Other causes of anemia (sickle cell disease, thalassemia, other hemolytic anemia, bone marrow failure, etc.) apparent by history, physical examination, and/or laboratory tests.~7. High likelihood of suboptimal adherence by parents with study requirements (previous missed clinic visits)~8. Inability to tolerate oral medications~9. History of birth at \< 30 weeks gestation~10. Other medical or social factors at discretion of treating physician

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 48 Months
- Healthy Volunteers: f

Study Arms:
- NovaFerrum® (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.
- Ferrous Sulfate (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).